Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hyperlipoproteinemias
  Free Subscription

Articles published in
Circulation
    April 2024
  1. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
    HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
    Circulation. 2024;149:1183-1201.
    >> Share

    February 2024
  2. STONE NJ, Blum C
    If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
    Circulation. 2024;149:427-429.
    >> Share

    January 2024
  3. SANTOS RD, Cuchel M
    LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
    Circulation. 2024;149:363-366.
    >> Share

    November 2023
  4. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
    BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
    Circulation. 2023;148:1764-1777.
    >> Share

  5. MILES J, Scotti A, Castagna F, Kuno T, et al
    Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
    Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
    >> Share

    October 2023
  6. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
    >> Share

  7. RAAL F, Durst R, Bi R, Talloczy Z, et al
    Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
    >> Share

    September 2023
  8. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
    Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1057.
    >> Share

  9. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
    Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1059-1060.
    >> Share

  10. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    >> Share

    July 2023
  11. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    >> Share

    May 2023
  12. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    >> Share

    April 2023
  13. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    >> Share

    February 2023
  14. PAN C, Herrero-Fernandez B, Borja Almarcha C, Gomez Bris R, et al
    Time-Restricted Feeding Enhances Early Atherosclerosis in Hypercholesterolemic Mice.
    Circulation. 2023;147:774-777.
    >> Share

    October 2022
  15. SHOTWELL MK, Vorla M, Kalra DK
    Very High Cholesterol Mimicking Homozygous Familial Hypercholesterolemia.
    Circulation. 2022;146:1182-1188.
    >> Share

    August 2022
  16. RIDKER PM, Rifai N, MacFadyen J, Glynn RJ, et al
    Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholi
    Circulation. 2022;146:372-379.
    >> Share

    May 2022
  17. BERGMARK BA, Marston NA, Bramson CR, Curto M, et al
    Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Circulation. 2022;145:1377-1386.
    >> Share

    February 2022
  18. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    >> Share

    June 2021
  19. KUEHN BM
    Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag.
    Circulation. 2021;143:2494-2496.
    >> Share

    March 2021

  20. Correction to: Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
    Circulation. 2021;143:e799.
    >> Share

    November 2020
  21. KULLO IJ
    Familial Hypercholesterolemia: A Reportable Disorder.
    Circulation. 2020;142:1999-2001.
    >> Share

    October 2020
  22. MSZAR R, Nasir K, Santos RD
    Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?
    Circulation. 2020;142:1405-1407.
    >> Share

    November 2019
  23. DAMASK A, Steg PG, Schwartz GG, Szarek M, et al
    Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016